Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:00 pm Sale | 2023-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | TANG CAPITAL PARTNERS LP | 0 0.000% | -4,215,864 (Position Closed) | Filing History |
| 2023-05-05 4:37 pm Purchase | 2023-05-03 | 13G | TCR2 Therapeutics Inc. TCRR | TANG CAPITAL PARTNERS LP | 4,215,864 10.700% | 1,476,917 (+53.92%) | Filing History |
| 2023-02-14 4:00 pm Sale | 2022-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | TANG CAPITAL PARTNERS LP | 2,738,947 7.100% | -61,053 (-2.18%) | Filing History |
| 2023-02-08 5:51 pm Sale | 2022-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | K2 PRINCIPAL FUND L.P. | 0 0.000% | -1,950,628 (Position Closed) | Filing History |
| 2022-08-31 6:13 pm Purchase | 2022-08-26 | 13G | TCR2 Therapeutics Inc. TCRR | K2 PRINCIPAL FUND L.P. | 1,950,628 5.050% | 1,950,628 (New Position) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | TCR2 Therapeutics Inc. TCRR | BlackRock Inc. BLK | 1,037,694 2.700% | -1,364,051 (-56.79%) | Filing History |
| 2022-03-04 4:00 pm Purchase | 2022-02-22 | 13G | TCR2 Therapeutics Inc. TCRR | TANG CAPITAL PARTNERS LP | 2,800,000 7.300% | 2,800,000 (New Position) | Filing History |
| 2022-02-14 5:07 pm Sale | 2021-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | Redmile Group, LLC | 1,346,058 3.500% | -1,486,830 (-52.48%) | Filing History |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | BlackRock Inc. BLK | 2,401,745 6.300% | -201,794 (-7.75%) | Filing History |
| 2021-11-10 08:51 am Sale | 2021-10-29 | 13G | TCR2 Therapeutics Inc. TCRR | WELLINGTON MANAGEMENT GROUP LLP | 1,131,347 2.960% | -2,622,017 (-69.86%) | Filing History |
| 2021-02-16 4:09 pm Purchase | 2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | Redmile Group, LLC | 2,832,888 8.500% | 1,033,700 (+57.45%) | Filing History |
| 2021-02-16 1:29 pm Sale | 2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | ArrowMark Colorado Holdings LLC | 1,167,220 3.500% | -102,546 (-8.08%) | Filing History |
| 2021-02-09 06:17 am Sale | 2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | Upnorth Investment Ltd | 1,281,392 3.800% | -856,027 (-40.05%) | Filing History |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | BlackRock Inc. BLK | 2,603,539 7.800% | 2,603,539 (New Position) | Filing History |
| 2021-01-11 09:10 am Purchase | 2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | WELLINGTON MANAGEMENT GROUP LLP | 3,753,364 11.230% | 3,753,364 (New Position) | Filing History |